Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rheumatic Heart Disease I: Introduction

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healing.

Bioactive materials·2026

Same author

IL-22BP Attenuates Right Ventricular Remodeling in Pulmonary Arterial Hypertension.

Clinical science (London, England : 1979)·2026

Same author

Validation of Smartwatches Integrated With Photoplethysmography for Continuous Evaluation of Atrial Fibrillation Burden.

JACC. Clinical electrophysiology·2026

Same author

Female Sex Is Not a Uniform Risk Factor in Atrial Fibrillation.

JACC. Advances·2026

Same author

Short Sleep Duration Measured by Smartwatch Is Associated With Elevated Resting Heart Rate and Reduced Nocturnal Oxygen Saturation: Insights From Heartbeat.

Journal of cardiovascular electrophysiology·2026

Same author

Catheter ablation of atrial fibrillation in patients with heart failure - preserved and reduced ejection fraction - real world evidence.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026

Same journal

Closing Diabetes Disparities-Is Technology Access Enough?

JAMA network open·2026

Same journal

Clinician Use of Home-Based Medical Care for Medicaid Beneficiaries.

JAMA network open·2026

Same journal

Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial.

JAMA network open·2026

Same journal

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma.

JAMA network open·2026

Same journal

Breast Cancer Survival in Asian American Patients.

JAMA network open·2026

Same journal

Social Determinants of Health and Continuous Glucose Monitoring Metrics in Type 1 or Type 2 Diabetes.

JAMA network open·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

Adverse Cardiovascular Outcomes in Patients With Syphilis.

Eli Tsakiris¹, Han Feng¹, Ghassan Bidaoui¹

¹Tulane Research Innovation for Arrhythmia Discovery, New Orleans, Louisiana.

JAMA Network Open

|April 13, 2026

Summary

This summary is machine-generated.

Syphilis infection significantly increases the risk of major cardiovascular events, including stroke and myocardial infarction. Early detection and cardiovascular risk assessment are crucial for managing syphilis patients.

Related Experiment Videos

Last Updated: Apr 14, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

Area of Science:

Cardiology
Infectious Diseases
Public Health

Background:

Syphilis (Treponema pallidum) has historical links to cardiovascular complications.
Recent resurgence in US syphilis incidence necessitates evaluation of its independent cardiovascular impact.

Purpose of the Study:

To determine if syphilis infection independently elevates the risk of adverse cardiovascular outcomes.
To assess cardiovascular risks in a US health system population with syphilis.

Main Methods:

Retrospective cohort study with 15-year follow-up (2011-2025) in New Orleans.
Adults with syphilis (ICD-10 codes) compared to matched controls without syphilis.
Exclusion of participants with pre-existing cardiovascular disease.

Main Results:

Syphilis associated with increased risk of aortic aneurysm/dissection (HR 2.08), ischemic stroke (HR 1.53), hemorrhagic stroke (HR 1.92), peripheral artery disease (HR 1.28), death (HR 5.80), and myocardial infarction (HR 1.33).
No significant association found for heart failure, atrial fibrillation, aortic regurgitation, or venous thromboembolism.

Conclusions:

Syphilis infection is an independent risk factor for several major cardiovascular outcomes.
Highlights the importance of early syphilis detection and treatment.
Suggests integrating cardiovascular risk assessment into syphilis management.